million people affected worldwide
Psychedelic research currently is in Preclinical
About 30% or one in three of those suffering from depression are dealing with so-called treatment-resistant depression (TRD). The name refers to that these patients have tried at least two treatment options, without success. Psychedelics may offer hope to those suffering from TRD.
This topic is currently a stub, it will be expanded upon in the near future.
These are the institutes, from companies to universities, who are working on Treatment-Resistant Depression.
Revixia Life Sciences is a biotech company developing Salvinorin A (salvia) for substance use disorders (SUD), treatment-resistant depression (TRD), and pain.
These are some of the best-known people, from researchers to entrepreneurs, working on Treatment-Resistant Depression.
George Goldsmith is the CEO, Co-Founder, and Chairman of Compass Pathways, which he has led since July 2016.
Linked Research Papers & Trials
Pro & Business members will be able to see all linked papers and trials directly on this topic page.
See the information directly on this page with a paid membership.